Table 4.

mRNA content of major proteins involved in the regulation of liver de novo lipogenesis

	Control	DIO	DIOcit–stat	DIOstat	DIOcit
Lxrα	0.95 ± 0.14	1.37 ± 0.13*	0.61 ± 0.08$	1.26 ± 0.11	1.08 ± 0.12
Chrebp	0.98 ± 0.15	1.73 ± 0.26*	0.99 ± 0.15	1.68 ± 0.19*	1.72 ± 0.17*
PPAR α	0.92 ± 0.09	1.32 ± 0.15	0.67 ± 0.10*	0.78 ± 0.10*	1.41 ± 0.18
Pgc‐1α	1.37 ± 0.20	1.02 ± 0.12*	0.98 ± 0.08*	0.81 ± 0.07*	1.55 ± 0.25
PPAR γ	0.73 ± 0.09	1.31 ± 0.27*	0.60 ± 0.06#	1.08 ± 0.11	1.16 ± 0.11*
Acc1	1.07 ± 0.10	0.92 ± 0.08*	0.68 ± 0.03$	1.41 ± 0.14	1.29 ± 0.07
Fasn	1.83 ± 0.24	1.21 ± 0.10*	0.71 ± 0.06$	1.18 ± 0.11*	1.14 ± 0.08*
Scd1	1.64 ± 0.21	1.80 ± 0.44	0.36 ± 0.03$	0.86 ± 0.14	1.02 ± 0.13
Gpam	1.13 ± 0.11	1.14 ± 0.12	1.02 ± 0.16	1.15 ± 0.11	1.23 ± 0.07
eNOS	1.60 ± 0.21	1.14 ± 0.11*	0.96 ± 0.09*	0.91 ± 0.12*	0.99 ± 0.10*

Pgc‐1α, peroxisome proliferator‐activated receptor gamma coactivator 1‐α.

Results are expressed relative to Hprt gene expression (mean ± SEM, n = 10 per group). Dietary interventions: standard diet (control), high fat–high sucrose diet (DIO) and DIO enriched in citrulline (2.5 g∙kg⁻¹) (DIOcit), atorvastatin (10 mg∙kg⁻¹) (DIOstat) or citrulline and atorvastatin (DIOcit–stat).

^* P < 0.05, significantly different from controls;

^$ P < 0.05, significantly different from control and other DIO groups.

^# P < 0.05, significantly different from other DIO groups.